Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of inhaled EXO-CD24 in adults with ARDS
MOH_2023-05-08_012614Phase 2Recruiting
- Sponsor
- Nano24
- Start
- Apr 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing EXO-CD24 with Placebo (2 arms). Primary endpoints: Safety of EXO-CD24 and Efficacy of EXO-CD24 in preventing clinical deterioration. Started Apr 2023; status: recruiting.
02
Drugs
exosomes overexpressing CD24
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on MOH_2023-05-08_012614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-08_012614.